Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 73Plasma cell 60Other hematologic neoplasm 27Genitourinary 6Gynecologic 4Gastrointestinal 4Myeloid 3Thoracic 2Head & Neck 2Tumor-Agnostic 1Sarcoma 1Endocrine 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 12Whole-Body Irradiation 11Peripheral Blood Stem Cell Transplantation 11Cyclophosphamide 11Mycophenolic Acid 9fludarabine 7Cyclosporine 6Busulfan 6Tacrolimus 4Melphalan 4Filgrastim 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Antilymphocyte Serum 4eltrombopag 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Alemtuzumab 3AP 1903 reagent 3romiplostim 2Transplantation 2Topotecan 2Thiotepa 2Sirolimus 2SRA737 2Radiotherapy 2Gene Expression Profiling 2Etoposide 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lenalidomide × Classical hematology × Clear all
NCT00352001 2018-09-19

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

Case Comprehensive Cancer Center

Phase 1/2 Completed
37 enrolled 14 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡